Mizuho lowered the firm’s price target on BridgeBio to $53 from $60 and keeps a Buy rating on the shares after the company granted Bayer an exclusive license to commercialize acoramidis for transthyretin amyloid cardiomyopathy in Europe, for up to $310M in upfront and near-term milestone payments plus royalties. The firm says the deal makes fundamental, operational and financial sense.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- BridgeBio, Bayer announce European licensing agreement for acoramidis
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio price target raised to $46 from $42 at Citi
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
